Latest NewsSep 25, 2025HiFiBiO Therapeutics to Present Updated Phase 1 Clinical Data of Two Immuno-Oncology Programs at the 2025 Annual Meeting of the European Society for Medical Oncology (ESMO) All Filter By: Year20252024202320222021202020192018201720162015Jul 3, 2020HFB9-2, a novel Galectin-9 neutralizing antibody to reverse immune suppression in the tumor microenvironmentJul 3, 2020Discovery and characterization of novel TNFR2 antibodies to modulate T cell activities in immunosuppressive environmentJul 3, 2020HFB301001, a novel OX40 agonistic antibody with a unique pharmacological profile and innovative biomarker strategyJun 22, 2020HiFiBiO Therapeutics Presents Three Novel Immuno-Oncology Programs at 2020 AACR Virtual Annual Meeting IIMay 15, 2020HiFiBiO Therapeutics Unveils Several Novel Antibodies Showing Promise to Be Precision Immunotherapies for Cancer Patients< 1 … 10 11 12 13 14 … 18 >
